Article
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Nature communications - 28 Mar 2024
Hayes Tikvah K, Aquilanti Elisa, Persky Nicole S, Yang Xiaoping, Kim Erica E, Brenan Lisa, Goodale Amy B, Alan Douglas, Sharpe Ted, Shue Robert E, Westlake Lindsay, Golomb Lior, Silverman Brianna R, Morris Myshal D, Fisher Ty Running, Beyene Eden, Li Yvonne Y, Cherniack Andrew D, Piccioni Federica, Hicks J Kevin, Chi Andrew S, Cahill Daniel P, Dietrich Jorg, Batchelor Tracy T, Root David E, Johannessen Cory M, Meyerson Matthew
Abstract excerpt
The epidermal growth factor receptor, EGFR, is frequently activated in lung cancer and glioblastoma by genomic alterations including missense mutations. The different mutation spectra in these diseases are reflected in divergent responses to EGFR inhibition: significant patient benefit in lung cancer, but limited in glioblastoma. Here, we report a comprehensive mutational analysis of EGFR function. We perform...
Topics
- Humans
- Glioblastoma
- Protein Kinase Inhibitors
- ErbB Receptors
- Lung Neoplasms
- Mutation